Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.23
ELGX's Cash to Debt is ranked higher than
72% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.03 vs. ELGX: 1.23 )
ELGX' s 10-Year Cash to Debt Range
Min: 1.23   Max: No Debt
Current: 1.23

Equity to Asset 0.50
ELGX's Equity to Asset is ranked higher than
62% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. ELGX: 0.50 )
ELGX' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.96
Current: 0.5

0.41
0.96
F-Score: 3
Z-Score: 4.78
M-Score: -2.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -19.75
ELGX's Operating margin (%) is ranked higher than
55% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.92 vs. ELGX: -19.75 )
ELGX' s 10-Year Operating margin (%) Range
Min: -237.33   Max: -4.47
Current: -19.75

-237.33
-4.47
Net-margin (%) -21.97
ELGX's Net-margin (%) is ranked higher than
56% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.36 vs. ELGX: -21.97 )
ELGX' s 10-Year Net-margin (%) Range
Min: -228.8   Max: 15.84
Current: -21.97

-228.8
15.84
ROE (%) -26.21
ELGX's ROE (%) is ranked higher than
56% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.53 vs. ELGX: -26.21 )
ELGX' s 10-Year ROE (%) Range
Min: -56.88   Max: 15.58
Current: -26.21

-56.88
15.58
ROA (%) -12.64
ELGX's ROA (%) is ranked higher than
57% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. ELGX: -12.64 )
ELGX' s 10-Year ROA (%) Range
Min: -50.63   Max: 11.48
Current: -12.64

-50.63
11.48
ROC (Joel Greenblatt) (%) -82.72
ELGX's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. ELGX: -82.72 )
ELGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1382.35   Max: -22.12
Current: -82.72

-1382.35
-22.12
Revenue Growth (3Y)(%) 15.40
ELGX's Revenue Growth (3Y)(%) is ranked higher than
92% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ELGX: 15.40 )
ELGX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -41.8   Max: 66.8
Current: 15.4

-41.8
66.8
EBITDA Growth (3Y)(%) -7.80
ELGX's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 225 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ELGX: -7.80 )
ELGX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -50   Max: 73.8
Current: -7.8

-50
73.8
EPS Growth (3Y)(%) -0.70
ELGX's EPS Growth (3Y)(%) is ranked higher than
70% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. ELGX: -0.70 )
ELGX' s 10-Year EPS Growth (3Y)(%) Range
Min: -51.6   Max: 128.9
Current: -0.7

-51.6
128.9
» ELGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ELGX Guru Trades in Q1 2014

Paul Tudor Jones 17,562 sh (New)
Pioneer Investments 571,453 sh (+44.97%)
Jim Simons Sold Out
Ron Baron Sold Out
Steven Cohen Sold Out
» More
Q2 2014

ELGX Guru Trades in Q2 2014

Pioneer Investments 585,991 sh (+2.54%)
Paul Tudor Jones Sold Out
» More
Q3 2014

ELGX Guru Trades in Q3 2014

Steven Cohen 216,452 sh (New)
Pioneer Investments 738,560 sh (unchged)
» More
Q4 2014

ELGX Guru Trades in Q4 2014

Steven Cohen Sold Out
Pioneer Investments 689,134 sh (-6.69%)
» More
» Details

Insider Trades

Latest Guru Trades with ELGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.93
ELGX's P/B is ranked higher than
51% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. ELGX: 8.93 )
ELGX' s 10-Year P/B Range
Min: 1.69   Max: 14.14
Current: 8.93

1.69
14.14
P/S 7.41
ELGX's P/S is ranked higher than
53% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. ELGX: 7.41 )
ELGX' s 10-Year P/S Range
Min: 1.14   Max: 53.43
Current: 7.41

1.14
53.43
EV-to-EBIT -37.53
ELGX's EV-to-EBIT is ranked higher than
56% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.15 vs. ELGX: -37.53 )
ELGX' s 10-Year EV-to-EBIT Range
Min: -178.3   Max: -3.3
Current: -37.53

-178.3
-3.3
Current Ratio 4.99
ELGX's Current Ratio is ranked higher than
88% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. ELGX: 4.99 )
ELGX' s 10-Year Current Ratio Range
Min: 2.58   Max: 20.25
Current: 4.99

2.58
20.25
Quick Ratio 3.93
ELGX's Quick Ratio is ranked higher than
88% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.79 vs. ELGX: 3.93 )
ELGX' s 10-Year Quick Ratio Range
Min: 2.29   Max: 19.04
Current: 3.93

2.29
19.04
Days Inventory 229.03
ELGX's Days Inventory is ranked higher than
54% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.27 vs. ELGX: 229.03 )
ELGX' s 10-Year Days Inventory Range
Min: 120.76   Max: 1408.32
Current: 229.03

120.76
1408.32
Days Sales Outstanding 64.58
ELGX's Days Sales Outstanding is ranked higher than
74% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.40 vs. ELGX: 64.58 )
ELGX' s 10-Year Days Sales Outstanding Range
Min: 6.64   Max: 125.56
Current: 64.58

6.64
125.56

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 47.20
ELGX's Price/Net Current Asset Value is ranked higher than
74% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. ELGX: 47.20 )
ELGX' s 10-Year Price/Net Current Asset Value Range
Min: 1.09   Max: 574
Current: 47.2

1.09
574
Price/Tangible Book 21.45
ELGX's Price/Tangible Book is ranked higher than
58% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. ELGX: 21.45 )
ELGX' s 10-Year Price/Tangible Book Range
Min: 0.81   Max: 114.8
Current: 21.45

0.81
114.8
Price/Median PS Value 1.00
ELGX's Price/Median PS Value is ranked higher than
86% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. ELGX: 1.00 )
ELGX' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 6.65
Current: 1

0.18
6.65
Earnings Yield (Greenblatt) -2.70
ELGX's Earnings Yield (Greenblatt) is ranked higher than
59% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. ELGX: -2.70 )
ELGX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.2   Max: 0
Current: -2.7

-3.2
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RM1.Germany,
Endologix Inc was incorporated in California on March 16, 1992 under the name Cardiovascular Dynamics, Inc. and reincorporated in Delaware in June 1993. The Company develops, manufactures, markets and sells medical devices for the treatment of abdominal aortic aneurysms (AAA). Its main products are intended for the treatment of AAA through minimally-invasive endovascular repair (EVAR) or endovascular sealing ('EVAS'), solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The Company's EVAR products consist of: a cobalt chromium alloy stent covered by polytetrafluoroethylene graft material; and an accompanying delivery system. The Company's EVAS product consists of: bilateral covered stents with endobags; a biocompatible polymer injected into the endobags to seal the aneurysm; and a delivery system and polymer dispenser. All of its products are manufactured, assembled, and packaged at its 60,000 square foot leased facilities in Irvine, California and markets and sells its products in the U.S. and in 11 Western European countries through a direct sales force and network of agents. The Company sells EVAR products through exclusive independent distributors or agents in 14 other European countries, Japan, 9 countries in South America, New Zealand and Mexico. Its main competitors include: Medtronic, Inc., W.L. Gore Inc., and Cook Medical Products, Inc., and new market entrants, TrvVascular, Inc. and Lombard Medical Technologies. The Company is subject to additional licensing and regulatory requirements relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for NAS:ELGX

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Endologix Inc Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Weekly CFO Sells Highlight: ELGX, LOW, NWS, SBUX, WLP Dec 18 2012 
Endologix Inc Reports Operating Results (10-K) Mar 16 2011 
Endologix Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 07 2010 
Endologix Inc Reports Operating Results (10-Q) Jul 30 2010 
Weekly CEO Sells Highlight: Cisco Systems Inc, AmerisourceBergen Corp, PAETEC HOLDING CORP, Endologi May 22 2010 
Endologix Inc (ELGX) CEO John D Mcdermott sells 225,000 Shares May 17 2010 
Endologix Inc Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
ENDOLOGIX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Mar 13 2015
Endologix Announces Chief Financial Officer Transition Mar 12 2015
ENDOLOGIX INC /DE/ Financials Mar 10 2015
10-K for Endologix, Inc. Mar 04 2015
Endologix to Present at the 27th Annual ROTH Conference Mar 03 2015
ENDOLOGIX INC /DE/ Files SEC form 10-K, Annual Report Mar 02 2015
Endologix reports 4Q loss Feb 25 2015
Endologix reports 4Q loss Feb 25 2015
Endologix Inc Earnings Call scheduled for 5:00 pm ET today Feb 25 2015
ENDOLOGIX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition Feb 25 2015
Endologix Reports 10% and 12% Revenue Growth for the Fourth Quarter and Full Year 2014 Feb 25 2015
Q4 2014 Endologix Inc Earnings Release - After Market Close Feb 25 2015
Endologix, Inc. (ELGX), Quest Diagnostics Inc (DGX), The Spectranetics Corporation (SPNC), and More:... Feb 12 2015
Endologix to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015 Jan 26 2015
Endologix to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 05 2015
ENDOLOGIX INC /DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 25 2014
Endologix to Participate in Two Investor Conferences in December Nov 25 2014
Nellix Clinical Data From the EVAS FORWARD Global Registry Presented at 2014 VEITH Symposium Nov 20 2014
Endologix Completes Patient Enrollment in the Nellix(R) EVAS FORWARD-IDE Clinical Trial Nov 18 2014
Endologix to Participate in Three Investor Conferences in November Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK